NeuroPace (NPCE) Deferred Taxes (2020 - 2021)
NeuroPace (NPCE) posted Deferred Taxes of -$47000.0 for Q4 2021, little changed on a QoQ basis from -$47000.0 in Q3 2021, and down 122.27% year-over-year from $211000.0 in Q4 2020.
Powered by 
Analysis
NeuroPace (NPCE) Deferred Taxes (2020 - 2021) Analysis & Trends
NeuroPace has reported Deferred Taxes for 2 years, with the latest figure at -$47000.0 in Q4 2021.
- On a quarterly basis, Deferred Taxes fell 122.27% year-over-year to -$47000.0 in Q4 2021; TTM through Sep 2022 was -$47000.0, a 84.74% increase from a year earlier, with the FY2021 full-year figure at -$566000.0, down 4616.67% from the prior year.
- Deferred Taxes was -$47000.0 for Q4 2021 at NeuroPace, roughly flat from -$47000.0 in the prior quarter.
- The five-year high for Deferred Taxes was $211000.0 in Q4 2020, with the low at -$294000.0 in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -31.00 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 127.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 107.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 17.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -181.30 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -300,000.00 |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 600,000.00 |
| 10 | NeuroPace | 493.15 Mn | 441.45 Mn | 18.91 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -47,000.00 |
| Sep 30, 2021 | -47,000.00 |
| Jun 30, 2021 | -294,000.00 |
| Mar 31, 2021 | -178,000.00 |
| Dec 31, 2020 | 211,000.00 |
| Sep 30, 2020 | -44,000.00 |
| Jun 30, 2020 | -105,000.00 |
| Mar 31, 2020 | -74,000.00 |